董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Grey | 男 | Director | 64 | 16.96万美元 | 未持股 | 2017-04-20 |
| Henry J. Fuchs | 男 | Director | 59 | 17.09万美元 | 未持股 | 2017-04-20 |
| Charles M. Baum | 男 | President and Chief Executive Officer, Director | 58 | 297.34万美元 | 未持股 | 2017-04-20 |
| Rodney W. Lappe | 男 | Executive Chairman of the Board | 62 | 18.71万美元 | 未持股 | 2017-04-20 |
| Bruce L. A. Carter | 男 | Director | 73 | 14.52万美元 | 未持股 | 2017-04-20 |
| Craig Johnson | 男 | Director | 55 | 17.84万美元 | 未持股 | 2017-04-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chris LeMasters | 男 | Executive Vice President and Chief Business Officer | 50 | 未披露 | 未持股 | 2017-04-20 |
| Jamie A. Donadio | 男 | Senior Vice President and Chief Financial Officer | 41 | 未披露 | 未持股 | 2017-04-20 |
| Charles M. Baum | 男 | President and Chief Executive Officer, Director | 58 | 297.34万美元 | 未持股 | 2017-04-20 |
| Isan Chen | 男 | Executive Vice President and Chief Medical and Development Officer | 54 | 168.84万美元 | 未持股 | 2017-04-20 |
| James Christensen | 男 | Senior Vice President and Chief Scientific Officer | 48 | 174.73万美元 | 未持股 | 2017-04-20 |
董事简历
中英对照 | 中文 | 英文- Michael Grey
-
Michael Grey，自2017年4月起担任董事会执行主席，并于2021年11月至2022年1月担任Spruce Biosciences, Inc.临时首席执行官。此外，Grey先生自2020年1月起担任上市生物制药公司Mirum Pharmaceuticals, Inc.的董事长，并自2018年5月起担任Mirum的董事。Grey先生此前曾于2019年3月至2019年12月担任Mirum执行主席，并于2018年5月至2019年3月担任Mirum首席执行官。Grey先生于2017年12月至2024年10月担任Reneo Pharmaceuticals，Inc.（于2024年与生物制药公司OnKure，Inc.合并）的执行主席，并自2024年10月起担任OnKure的董事。Grey先生自2020年9月起担任Plexium执行董事长。他自2021年5月起担任私营制药公司Sorriso Pharmaceuticals，Inc.的董事长，并自2023年11月起担任私营生物技术公司Theolytics Ltd.的执行主席。Grey先生此前曾于2005年12月至2021年5月担任BioMarin的董事，并于2014年11月至2021年6月担任生物制药公司Mirati Therapeutics, Inc.的董事。他还自2010年1月起担任风险投资公司Pappas Ventures的风险合伙人，于2019年1月至2020年4月担任私营生物制药公司Curzion Pharmaceuticals，Inc.的董事，该公司于2020年4月被Horizon收购，并于2011年9月至2023年10月担任Horizon的董事。Grey先生于2019年1月至2019年9月担任Curzion总裁兼首席执行官，于2015年10月至2017年1月担任Amplyx Pharmaceuticals，Inc.总裁兼首席执行官，并于2014年9月至2017年12月担任Reneo董事长兼首席执行官。2011年2月至2014年6月，Grey先生担任Lumena Pharmaceuticals, Inc.的总裁兼首席执行官，该公司于2014年6月被Shire plc收购。Grey先生在制药和生物技术行业拥有超过45年的经验，曾在多家公司担任高级职务，包括SGX Pharmaceuticals，Inc.（于2008年出售给Eli Lilly and Company）的总裁兼首席执行官、Trega Biosciences，Inc.（于2001年出售给LION Bioscience，Inc.）的总裁兼首席执行官以及BioChem Therapeutic Inc.的总裁。在此之前，Grey先生曾在Glaxo，Inc.和Glaxo Holdings PLC担任多个职务，最终担任公司发展副总裁和国际许可总监。Grey先生在英国Nottingham大学获得化学学士学位。
Michael Grey,has served as Executive Chairman of the Board since April 2017 and served as Spruce Biosciences, Inc. Interim Chief Executive Officer from November 2021 to January 2022. In addition, Mr. Grey has served as Chairman of Mirum Pharmaceuticals, Inc., a public biopharmaceutical company, since January 2020, and has been a director of Mirum since May 2018. Mr. Grey previously served as Executive Chairman of Mirum from March 2019 to December 2019 and Chief Executive Officer of Mirum from May 2018 to March 2019. Mr. Grey served as Executive Chairman of Reneo Pharmaceuticals, Inc. from December 2017 to October 2024 (merged with OnKure, Inc., a biopharmaceutical company, in 2024) and has served as a director for OnKure since October 2024. Mr. Grey has served as Executive Chairman of Plexium since September 2020. He has served as Chairman of Sorriso Pharmaceuticals, Inc., a private pharmaceutical company since May 2021 and as Executive Chair of Theolytics Ltd., a private biotechnology company, since November 2023. Mr. Grey previously served as a director of BioMarin from December 2005 to May 2021 and as director of Mirati Therapeutics, Inc., a biopharmaceutical company, from November 2014 to June 2021. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010, as a director of Curzion Pharmaceuticals, Inc., a private biopharmaceutical company, which was acquired in April 2020 by Horizon, from January 2019 to April 2020, and as a director at Horizon from September 2011 to October 2023. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion, from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001), and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc., and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey received a B.S. in chemistry from the University of Nottingham in the United Kingdom. - Michael Grey，自2017年4月起担任董事会执行主席，并于2021年11月至2022年1月担任Spruce Biosciences, Inc.临时首席执行官。此外，Grey先生自2020年1月起担任上市生物制药公司Mirum Pharmaceuticals, Inc.的董事长，并自2018年5月起担任Mirum的董事。Grey先生此前曾于2019年3月至2019年12月担任Mirum执行主席，并于2018年5月至2019年3月担任Mirum首席执行官。Grey先生于2017年12月至2024年10月担任Reneo Pharmaceuticals，Inc.（于2024年与生物制药公司OnKure，Inc.合并）的执行主席，并自2024年10月起担任OnKure的董事。Grey先生自2020年9月起担任Plexium执行董事长。他自2021年5月起担任私营制药公司Sorriso Pharmaceuticals，Inc.的董事长，并自2023年11月起担任私营生物技术公司Theolytics Ltd.的执行主席。Grey先生此前曾于2005年12月至2021年5月担任BioMarin的董事，并于2014年11月至2021年6月担任生物制药公司Mirati Therapeutics, Inc.的董事。他还自2010年1月起担任风险投资公司Pappas Ventures的风险合伙人，于2019年1月至2020年4月担任私营生物制药公司Curzion Pharmaceuticals，Inc.的董事，该公司于2020年4月被Horizon收购，并于2011年9月至2023年10月担任Horizon的董事。Grey先生于2019年1月至2019年9月担任Curzion总裁兼首席执行官，于2015年10月至2017年1月担任Amplyx Pharmaceuticals，Inc.总裁兼首席执行官，并于2014年9月至2017年12月担任Reneo董事长兼首席执行官。2011年2月至2014年6月，Grey先生担任Lumena Pharmaceuticals, Inc.的总裁兼首席执行官，该公司于2014年6月被Shire plc收购。Grey先生在制药和生物技术行业拥有超过45年的经验，曾在多家公司担任高级职务，包括SGX Pharmaceuticals，Inc.（于2008年出售给Eli Lilly and Company）的总裁兼首席执行官、Trega Biosciences，Inc.（于2001年出售给LION Bioscience，Inc.）的总裁兼首席执行官以及BioChem Therapeutic Inc.的总裁。在此之前，Grey先生曾在Glaxo，Inc.和Glaxo Holdings PLC担任多个职务，最终担任公司发展副总裁和国际许可总监。Grey先生在英国Nottingham大学获得化学学士学位。
- Michael Grey,has served as Executive Chairman of the Board since April 2017 and served as Spruce Biosciences, Inc. Interim Chief Executive Officer from November 2021 to January 2022. In addition, Mr. Grey has served as Chairman of Mirum Pharmaceuticals, Inc., a public biopharmaceutical company, since January 2020, and has been a director of Mirum since May 2018. Mr. Grey previously served as Executive Chairman of Mirum from March 2019 to December 2019 and Chief Executive Officer of Mirum from May 2018 to March 2019. Mr. Grey served as Executive Chairman of Reneo Pharmaceuticals, Inc. from December 2017 to October 2024 (merged with OnKure, Inc., a biopharmaceutical company, in 2024) and has served as a director for OnKure since October 2024. Mr. Grey has served as Executive Chairman of Plexium since September 2020. He has served as Chairman of Sorriso Pharmaceuticals, Inc., a private pharmaceutical company since May 2021 and as Executive Chair of Theolytics Ltd., a private biotechnology company, since November 2023. Mr. Grey previously served as a director of BioMarin from December 2005 to May 2021 and as director of Mirati Therapeutics, Inc., a biopharmaceutical company, from November 2014 to June 2021. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010, as a director of Curzion Pharmaceuticals, Inc., a private biopharmaceutical company, which was acquired in April 2020 by Horizon, from January 2019 to April 2020, and as a director at Horizon from September 2011 to October 2023. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion, from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001), and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc., and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey received a B.S. in chemistry from the University of Nottingham in the United Kingdom.
- Henry J. Fuchs
-
Henry J. Fuchs， 2009年3月加入BioMarin，现任执行副总裁和首席医疗官。从2009年3月到2009年12月担任高级副总裁和首席医疗官。从2005年9月到2008年12月担任Onyx制药公司（一家生物制药公司）执行副总裁和首席医疗官。他是IntraBiotics公司（一家生物制药公司）首席执行官。他1996年最初加入IntraBiotics公司，担任临床事务副总裁，之后在2001年担任总裁和首席运营官。从1987年到1996年他在Genentech公司工作，担任多个职位，他领导的临床小组在 Herceptin（一种乳腺癌疗法）和 Pulmozyme（一种纤维囊肿疗法）的批准通过中起到了至关重要的作用。他持有乔治华盛顿大学硕士学位和哈佛学院生物化学理学学士学位。他担任Mirati Therapuetics （一家生物制药公司）和基因健康公司（一家诊断公司）董事，两家公司都在纳斯达克全球精选市场上市。
Henry J. Fuchs, M.D.From March 2009 to December 2009 Dr. Fuchs served as our Senior Vice President and Chief Medical Officer. From September 2005 until December 2008 Dr. Fuchs served as Executive Vice President and Chief Medical Officer for Onyx Pharmaceuticals, a biopharmaceutical company. Dr. Fuchs served as Chief Executive Officer of Ardea Biosciences, Inc. from January 2003 until June 2005. Dr. Fuchs first joined Ardea Biosciences, Inc. as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996 Dr. Fuchs held various positions at Genentech, Inc. where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme, a therapeutic for cystic fibrosis. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University. Dr. Fuchs is currently a director of Mirati Therapeutics, a public biopharmaceutical company, and Genomic Health, Inc., a public molecular diagnostics company. Dr. Fuchs was on the Board of Directors of Ardea Biosciences, Inc. from 1996 until its acquisition by AstraZenaca PLC in 2012. - Henry J. Fuchs， 2009年3月加入BioMarin，现任执行副总裁和首席医疗官。从2009年3月到2009年12月担任高级副总裁和首席医疗官。从2005年9月到2008年12月担任Onyx制药公司（一家生物制药公司）执行副总裁和首席医疗官。他是IntraBiotics公司（一家生物制药公司）首席执行官。他1996年最初加入IntraBiotics公司，担任临床事务副总裁，之后在2001年担任总裁和首席运营官。从1987年到1996年他在Genentech公司工作，担任多个职位，他领导的临床小组在 Herceptin（一种乳腺癌疗法）和 Pulmozyme（一种纤维囊肿疗法）的批准通过中起到了至关重要的作用。他持有乔治华盛顿大学硕士学位和哈佛学院生物化学理学学士学位。他担任Mirati Therapuetics （一家生物制药公司）和基因健康公司（一家诊断公司）董事，两家公司都在纳斯达克全球精选市场上市。
- Henry J. Fuchs, M.D.From March 2009 to December 2009 Dr. Fuchs served as our Senior Vice President and Chief Medical Officer. From September 2005 until December 2008 Dr. Fuchs served as Executive Vice President and Chief Medical Officer for Onyx Pharmaceuticals, a biopharmaceutical company. Dr. Fuchs served as Chief Executive Officer of Ardea Biosciences, Inc. from January 2003 until June 2005. Dr. Fuchs first joined Ardea Biosciences, Inc. as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996 Dr. Fuchs held various positions at Genentech, Inc. where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme, a therapeutic for cystic fibrosis. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University. Dr. Fuchs is currently a director of Mirati Therapeutics, a public biopharmaceutical company, and Genomic Health, Inc., a public molecular diagnostics company. Dr. Fuchs was on the Board of Directors of Ardea Biosciences, Inc. from 1996 until its acquisition by AstraZenaca PLC in 2012.
- Charles M. Baum
-
Charles M. Baum, M.D., Ph.D.，自2012年11月以来，担任本公司的总裁、首席执行官，以及是一位董事会成员。2003年6月-2012年9月期间，他曾在辉瑞（Pfizer）担任高级副总裁，负责辉瑞（Pfizer）全球研发部门的生物治疗法临床研究；以及担任副总裁、肿瘤学发展主管和首席医疗官，负责辉瑞（Pfizer）的生物疗法和生物创新中心。2000-2003年期间，他曾在被Merck 收购的公司-Schering-Plough负责数个抗肿瘤化合物的发展。他的职业生涯包括在Stanford大学和Emory大学的学术和医院职位，以及在医药行业担任的数个职责范围不断加大的职位，这些公司包括：SyStemix, Inc. （acquired by Novartis AG）， G.D. Searle & Company （acquired by Pfizer）， Schering-Plough Corporation （acquired by Merck） and Pfizer. Baum博士是在Missouri 州圣路易斯（St. Louis）的Washington大学医学院获得他的医学学士学位和医学博士学位（免疫学专业）的；以及是在斯坦福大学（Stanford University）完成他的博士后教育的。
Charles M. Baum has agreed to serve on our board of directors following the completion of this offering. Dr. Baum has been the President and Chief Executive Officer and a member of the board of directors of Mirati Therapeutics, Inc. since November 2012. From June 2003 to September 2012 he was at Pfizer as Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division and as Vice President and Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. From 2000 to 2003 he was responsible for the development of several oncology compounds at Schering-Plough Corporation acquired by Merck. His career has included academic and hospital positions at Stanford University and Emory University, as well as positions of increasing responsibility within the pharmaceutical industry at SyStemix, Inc. (acquired by Novartis AG), G.D. Searle & Company (acquired by Pfizer), Schering-Plough Corporation (acquired by Merck) and Pfizer. Dr. Baum has served on the board of directors of Immunomedics, Inc. (Nasdaq:IMMU) since February 2019 and was on the board of directors of Array BioPharma Inc. from 2014 until its acquisition by Pfizer in July 2019. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-doctoral training at Stanford University. - Charles M. Baum, M.D., Ph.D.，自2012年11月以来，担任本公司的总裁、首席执行官，以及是一位董事会成员。2003年6月-2012年9月期间，他曾在辉瑞（Pfizer）担任高级副总裁，负责辉瑞（Pfizer）全球研发部门的生物治疗法临床研究；以及担任副总裁、肿瘤学发展主管和首席医疗官，负责辉瑞（Pfizer）的生物疗法和生物创新中心。2000-2003年期间，他曾在被Merck 收购的公司-Schering-Plough负责数个抗肿瘤化合物的发展。他的职业生涯包括在Stanford大学和Emory大学的学术和医院职位，以及在医药行业担任的数个职责范围不断加大的职位，这些公司包括：SyStemix, Inc. （acquired by Novartis AG）， G.D. Searle & Company （acquired by Pfizer）， Schering-Plough Corporation （acquired by Merck） and Pfizer. Baum博士是在Missouri 州圣路易斯（St. Louis）的Washington大学医学院获得他的医学学士学位和医学博士学位（免疫学专业）的；以及是在斯坦福大学（Stanford University）完成他的博士后教育的。
- Charles M. Baum has agreed to serve on our board of directors following the completion of this offering. Dr. Baum has been the President and Chief Executive Officer and a member of the board of directors of Mirati Therapeutics, Inc. since November 2012. From June 2003 to September 2012 he was at Pfizer as Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division and as Vice President and Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. From 2000 to 2003 he was responsible for the development of several oncology compounds at Schering-Plough Corporation acquired by Merck. His career has included academic and hospital positions at Stanford University and Emory University, as well as positions of increasing responsibility within the pharmaceutical industry at SyStemix, Inc. (acquired by Novartis AG), G.D. Searle & Company (acquired by Pfizer), Schering-Plough Corporation (acquired by Merck) and Pfizer. Dr. Baum has served on the board of directors of Immunomedics, Inc. (Nasdaq:IMMU) since February 2019 and was on the board of directors of Array BioPharma Inc. from 2014 until its acquisition by Pfizer in July 2019. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-doctoral training at Stanford University.
- Rodney W. Lappe
-
Rodney W. Lappe, Ph.D.，自2012年6月以来，是本公司的一位董事会成员；自2013年7月以来，担任董事长。自2012年1月以来，曾在一家私有投资公司- Tavistock Life Sciences担任高级副总裁。2004年1月-2011年12月期间，他曾是Pfizer的全球研发集团副总裁，以及是California州San Diego市CovX的首席科技官。2008年，Lappe博士在Pfizer 收购CovX之后，加入了Pfizer。2000-2002年期间，他曾是Pharmacia的心血管和代谢疾病副总裁。他还曾是St. Louis市Pharmacia的一位现场经理。在加入Pharmacia之前，他曾在Wyeth、 Rorer Central Research、CIBA Geigy和Searle Pharmaceuticals担任各种职责范围不断加大的职位。他是在Blackburn大学获得学士学位，以及在Indiana大学获得他的药物学医学博士学位的。
Rodney W. Lappe, Ph.D. has served as a member of our Board of Directors since June 2012 as Chairman of the Board since July 2013 and as Executive Chairman of the Board since June 2016. Since January 2012 Dr. Lappe has served as the Senior Vice President of Tavistock Life Sciences, a private investment firm. From January 2004 to December 2011 Dr. Lappe was Group Senior Vice President, Pfizer Worldwide Research and Development and Chief Scientific Officer for CovX in San Diego, California. Dr. Lappe joined Pfizer with the CovX acquisition in 2008. From 2000 to 2002 Dr. Lappe served as Vice President for cardiovascular and metabolic diseases at Pharmacia. He was also site leader for Pharmacia in St. Louis. Prior to joining Pharmacia, he held positions of increasing responsibility with Wyeth, Rorer Central Research, CIBA Geigy and Searle Pharmaceuticals. Dr. Lappe received his B.A. from Blackburn College and his Ph.D. in Pharmacology from Indiana University. - Rodney W. Lappe, Ph.D.，自2012年6月以来，是本公司的一位董事会成员；自2013年7月以来，担任董事长。自2012年1月以来，曾在一家私有投资公司- Tavistock Life Sciences担任高级副总裁。2004年1月-2011年12月期间，他曾是Pfizer的全球研发集团副总裁，以及是California州San Diego市CovX的首席科技官。2008年，Lappe博士在Pfizer 收购CovX之后，加入了Pfizer。2000-2002年期间，他曾是Pharmacia的心血管和代谢疾病副总裁。他还曾是St. Louis市Pharmacia的一位现场经理。在加入Pharmacia之前，他曾在Wyeth、 Rorer Central Research、CIBA Geigy和Searle Pharmaceuticals担任各种职责范围不断加大的职位。他是在Blackburn大学获得学士学位，以及在Indiana大学获得他的药物学医学博士学位的。
- Rodney W. Lappe, Ph.D. has served as a member of our Board of Directors since June 2012 as Chairman of the Board since July 2013 and as Executive Chairman of the Board since June 2016. Since January 2012 Dr. Lappe has served as the Senior Vice President of Tavistock Life Sciences, a private investment firm. From January 2004 to December 2011 Dr. Lappe was Group Senior Vice President, Pfizer Worldwide Research and Development and Chief Scientific Officer for CovX in San Diego, California. Dr. Lappe joined Pfizer with the CovX acquisition in 2008. From 2000 to 2002 Dr. Lappe served as Vice President for cardiovascular and metabolic diseases at Pharmacia. He was also site leader for Pharmacia in St. Louis. Prior to joining Pharmacia, he held positions of increasing responsibility with Wyeth, Rorer Central Research, CIBA Geigy and Searle Pharmaceuticals. Dr. Lappe received his B.A. from Blackburn College and his Ph.D. in Pharmacology from Indiana University.
- Bruce L. A. Carter
-
Bruce L. A. Carter，博士，于2012年6月担任Enanta Pharmaceuticals, Inc.公司董事会成员。于2008年6月担任Dr. Reddy’s Laboratories Limited公司董事会成员，该公司是一家公共持股的制药公司。2009年至2013年，他担任一家私人持股的生物技术公司Immune Design Corp.董事会成员。1998年4月至2009年1月，他担任一家公共持股的生物技术公司ZymoGenetics, Inc.的CEO，该公司于2010年10月被Bristol-Myers Squibb公司收购。1994年至2000年，他担任公共持股制药公司Novo Nordisk的首席科学家。他在伦敦大学伊丽莎白女王学院（Queen Elizabeth College, University of London ）获得微生物学博士学位，在英格兰诺丁汉大学（University of Nottingham, England）以优异成绩获得植物学理学学士学位。
Bruce L. A. Carter,has been an Affiliate Professor in the Department of Biochemistry at the University of Washington, Seattle, Washington since 1986. He served as Executive Chairman of Immune Design Corp., a privately held biotechnology company, from November 2009 to November 2011, and he served as a director from 2000 to January 2009. From 1998 to 2009, Dr. Carter served as President and Chief Executive Officer of ZymoGenetics, Inc., a public biotechnology company, and as its Chairman of the Board from 2005 until it was acquired by Bristol-Myers Squibb in October 2010. From 1994 to 1999, Dr. Carter was the Chief Scientific Officer of Novo Nordisk, a public pharmaceutical company. Previously he held positions in research at ZymoGenetics and G.D. Searle & Co. Ltd. Dr. Carter serves as a director of Mirati Therapeutics, a public biopharmaceutical company. He also previously served during the past five years as an independent director of Dr. Reddy's Laboratories Limited, a public pharmaceutical company. Dr. Carter holds a Ph.D. in microbiology from Queen Elizabeth College, University of London and a B.Sc. with Honors in botany from the University of Nottingham, England. - Bruce L. A. Carter，博士，于2012年6月担任Enanta Pharmaceuticals, Inc.公司董事会成员。于2008年6月担任Dr. Reddy’s Laboratories Limited公司董事会成员，该公司是一家公共持股的制药公司。2009年至2013年，他担任一家私人持股的生物技术公司Immune Design Corp.董事会成员。1998年4月至2009年1月，他担任一家公共持股的生物技术公司ZymoGenetics, Inc.的CEO，该公司于2010年10月被Bristol-Myers Squibb公司收购。1994年至2000年，他担任公共持股制药公司Novo Nordisk的首席科学家。他在伦敦大学伊丽莎白女王学院（Queen Elizabeth College, University of London ）获得微生物学博士学位，在英格兰诺丁汉大学（University of Nottingham, England）以优异成绩获得植物学理学学士学位。
- Bruce L. A. Carter,has been an Affiliate Professor in the Department of Biochemistry at the University of Washington, Seattle, Washington since 1986. He served as Executive Chairman of Immune Design Corp., a privately held biotechnology company, from November 2009 to November 2011, and he served as a director from 2000 to January 2009. From 1998 to 2009, Dr. Carter served as President and Chief Executive Officer of ZymoGenetics, Inc., a public biotechnology company, and as its Chairman of the Board from 2005 until it was acquired by Bristol-Myers Squibb in October 2010. From 1994 to 1999, Dr. Carter was the Chief Scientific Officer of Novo Nordisk, a public pharmaceutical company. Previously he held positions in research at ZymoGenetics and G.D. Searle & Co. Ltd. Dr. Carter serves as a director of Mirati Therapeutics, a public biopharmaceutical company. He also previously served during the past five years as an independent director of Dr. Reddy's Laboratories Limited, a public pharmaceutical company. Dr. Carter holds a Ph.D. in microbiology from Queen Elizabeth College, University of London and a B.Sc. with Honors in botany from the University of Nottingham, England.
- Craig Johnson
-
Craig Johnson，自2013年9月以来，是本公司董事会的一位成员。目前在数个生命科学公司的董事会任职。他目前是以下公司的一位董事：一家在纳斯达克（NASDAQ）上市的特殊医药公司- Heron Therapeutics股份有限公司、一家在纳斯达克（NASDAQ）上市的生物医药公司- Adamis医药公司和一家在纳斯达克（NASDAQ）上市的生物医药公司- La Jolla医药公司。他还曾在2008一直到Ardea Biosciences股份有限公司2012年被出售给阿斯利康（AstraZeneca PLC）之前，是一家纳斯达克（NASDAQ）上市生物技术公司- Ardea Biosciences股份有限公司的一位前董事。除了他的董事会任职，他曾在2012年以来，担任Daisas Medical有限责任公司的顾问。2011-2012年期间，他曾是PURE Bioscience股份有限公司的财务总监；2010-2011年期间，曾在NovaDel Pharma股份有限公司担任高级副总裁和财务总监。2004年一直到2009年TorreyPines Therapeutics股份有限公司被出售给Raptor Pharmaceuticals Corp.之前，在TorreyPines Therapeutics股份有限公司担任副总裁和财务总监；随后于2009-2010年期间，是Raptor医药公司一个独资子公司的副总裁。他曾担任数个职位，包括1994-2004年期间在MitoKor股份有限公司担任财务总监和业务高级副总裁。在1994年之前，他曾在数个早期科技公司担任数个高级财务职位，还曾在Price Waterhouse的一位注册会计师。Johnson先生是从Michigan大学Dearborn分校获得他的工商管理学士学位的。
Craig Johnson has served as a member of our Board of Directors since September 2013. Mr. Johnson serves on the boards of directors for several life science companies. He is currently a director for Heron Therapeutics, Inc., a NASDAQ-listed specialty pharmaceutical company, a position he has held since January 2014 as well as for La Jolla Pharmaceutical Company, a NASDAQ-listed biopharmaceutical company, a position he has held since October 2013. Mr. Johnson also serves as a director of GenomeDx Biosciences, a privately held biotechnology company, a position he has held since October 2015. Mr. Johnson also served as a past director of Adamis Pharmaceuticals Corporation, a NASDAQ-listed biopharmaceutical company, from 2011 to 2014 as well as Ardea Biosciences, Inc., a NASDAQ-listed biotechnology company, from 2008 until its sale to AstraZeneca PLC in June 2012. From 2011 to 2012 he was Chief Financial Officer of PURE Bioscience, Inc., and from 2010 to 2011 he was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009 and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions, including Chief Financial Officer and Senior Vice President of Operations, at MitoKor, Inc. from 1994 to 2004. Prior to 1994 Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his B.B.A. in accounting from the University of Michigan-Dearborn. - Craig Johnson，自2013年9月以来，是本公司董事会的一位成员。目前在数个生命科学公司的董事会任职。他目前是以下公司的一位董事：一家在纳斯达克（NASDAQ）上市的特殊医药公司- Heron Therapeutics股份有限公司、一家在纳斯达克（NASDAQ）上市的生物医药公司- Adamis医药公司和一家在纳斯达克（NASDAQ）上市的生物医药公司- La Jolla医药公司。他还曾在2008一直到Ardea Biosciences股份有限公司2012年被出售给阿斯利康（AstraZeneca PLC）之前，是一家纳斯达克（NASDAQ）上市生物技术公司- Ardea Biosciences股份有限公司的一位前董事。除了他的董事会任职，他曾在2012年以来，担任Daisas Medical有限责任公司的顾问。2011-2012年期间，他曾是PURE Bioscience股份有限公司的财务总监；2010-2011年期间，曾在NovaDel Pharma股份有限公司担任高级副总裁和财务总监。2004年一直到2009年TorreyPines Therapeutics股份有限公司被出售给Raptor Pharmaceuticals Corp.之前，在TorreyPines Therapeutics股份有限公司担任副总裁和财务总监；随后于2009-2010年期间，是Raptor医药公司一个独资子公司的副总裁。他曾担任数个职位，包括1994-2004年期间在MitoKor股份有限公司担任财务总监和业务高级副总裁。在1994年之前，他曾在数个早期科技公司担任数个高级财务职位，还曾在Price Waterhouse的一位注册会计师。Johnson先生是从Michigan大学Dearborn分校获得他的工商管理学士学位的。
- Craig Johnson has served as a member of our Board of Directors since September 2013. Mr. Johnson serves on the boards of directors for several life science companies. He is currently a director for Heron Therapeutics, Inc., a NASDAQ-listed specialty pharmaceutical company, a position he has held since January 2014 as well as for La Jolla Pharmaceutical Company, a NASDAQ-listed biopharmaceutical company, a position he has held since October 2013. Mr. Johnson also serves as a director of GenomeDx Biosciences, a privately held biotechnology company, a position he has held since October 2015. Mr. Johnson also served as a past director of Adamis Pharmaceuticals Corporation, a NASDAQ-listed biopharmaceutical company, from 2011 to 2014 as well as Ardea Biosciences, Inc., a NASDAQ-listed biotechnology company, from 2008 until its sale to AstraZeneca PLC in June 2012. From 2011 to 2012 he was Chief Financial Officer of PURE Bioscience, Inc., and from 2010 to 2011 he was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009 and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions, including Chief Financial Officer and Senior Vice President of Operations, at MitoKor, Inc. from 1994 to 2004. Prior to 1994 Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his B.B.A. in accounting from the University of Michigan-Dearborn.
高管简历
中英对照 | 中文 | 英文- Chris LeMasters
Chris LeMasters自2016年9月起担任我们的执行Vice President兼首席商务官。在加入Mirati之前，Lemasters先生于2015年8月至2016年9月担任Promosome（一家私人持有的生物疗法和生物仿制药公司）的首席执行官。此前，他曾担任几家生物治疗公司的高级管理职务，最近担任Tragara Pharmaceuticals公司（临床阶段癌症治疗公司）的联席创始人兼首席商务官（从2007年1月到2015年8月）。2006年5月至2007年12月，勒马斯特斯还担任Cabrellis Pharmaceuticals，Inc.的联合创始人兼首席商务官，他在该公司就Pharmion Corporation以1.04亿美元的价格收购该公司进行了谈判，并担任Vice President，从2004年4月到2006年5月，他曾担任Conforma Therapeutics公司的公司开发，在那里他曾谈判以2.5亿美元的价格被Biogen Idec公司收购。从1998年7月到2004年4月，Lemasters先生在礼来公司（Eli Lilly&Company）的企业业务发展集团任职，并负责一系列治疗领域的众多合作伙伴关系与许可的成功谈判。职业生涯早期，他曾担任Coopers&Lybrand Consulting公司的管理顾问，以及Owens Corning公司的运营审计师。他目前担任Aarden Pharmaceuticals公司（在那里他也是联合创始人）的董事会成员，以及the Hoosier Cancer Research Network（临床研究组织）的董事会成员，以及Promosome公司的董事会成员。
Chris LeMasters has served as our Executive Vice President and Chief Business Officer since September 2016. Prior to joining Mirati, Mr. LeMasters served as the Chief Executive Officer of Promosome, a privately held biotherapeutics and biosimilars company from August 2015 to September 2016. Previously, Mr. LeMasters held senior management positions at several biotherapeutics companies, most recently as co-founder and chief business officer of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company, a position he held from January 2007 to August 2015. Mr. LeMasters also served as Co-Founder and Chief Business Officer of Cabrellis Pharmaceuticals, Inc. from May 2006 to December 2007 where he negotiated its acquisition by Pharmion Corporation for $104 million, and as Vice President, Corporate Development of Conforma Therapeutics from April 2004 to May 2006 where he negotiated its acquisition by Biogen IDEC for $250 million. From July 1998 to April 2004 Mr. LeMasters worked in the Corporate Business Development group at Eli Lilly & Company and was responsible for the successful negotiation of numerous partnerships and licenses across a range of therapeutic areas. Earlier in his career, he was a management consultant with Coopers & Lybrand Consulting and an operational auditor with Owens Corning. Mr. LeMasters currently serves as a board member of Aarden Pharmaceuticals, where he is also a co-founder, and as a board member of the Hoosier Cancer Research Network, a clinical research organization and as a board member of Promosome.- Chris LeMasters自2016年9月起担任我们的执行Vice President兼首席商务官。在加入Mirati之前，Lemasters先生于2015年8月至2016年9月担任Promosome（一家私人持有的生物疗法和生物仿制药公司）的首席执行官。此前，他曾担任几家生物治疗公司的高级管理职务，最近担任Tragara Pharmaceuticals公司（临床阶段癌症治疗公司）的联席创始人兼首席商务官（从2007年1月到2015年8月）。2006年5月至2007年12月，勒马斯特斯还担任Cabrellis Pharmaceuticals，Inc.的联合创始人兼首席商务官，他在该公司就Pharmion Corporation以1.04亿美元的价格收购该公司进行了谈判，并担任Vice President，从2004年4月到2006年5月，他曾担任Conforma Therapeutics公司的公司开发，在那里他曾谈判以2.5亿美元的价格被Biogen Idec公司收购。从1998年7月到2004年4月，Lemasters先生在礼来公司（Eli Lilly&Company）的企业业务发展集团任职，并负责一系列治疗领域的众多合作伙伴关系与许可的成功谈判。职业生涯早期，他曾担任Coopers&Lybrand Consulting公司的管理顾问，以及Owens Corning公司的运营审计师。他目前担任Aarden Pharmaceuticals公司（在那里他也是联合创始人）的董事会成员，以及the Hoosier Cancer Research Network（临床研究组织）的董事会成员，以及Promosome公司的董事会成员。
- Chris LeMasters has served as our Executive Vice President and Chief Business Officer since September 2016. Prior to joining Mirati, Mr. LeMasters served as the Chief Executive Officer of Promosome, a privately held biotherapeutics and biosimilars company from August 2015 to September 2016. Previously, Mr. LeMasters held senior management positions at several biotherapeutics companies, most recently as co-founder and chief business officer of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company, a position he held from January 2007 to August 2015. Mr. LeMasters also served as Co-Founder and Chief Business Officer of Cabrellis Pharmaceuticals, Inc. from May 2006 to December 2007 where he negotiated its acquisition by Pharmion Corporation for $104 million, and as Vice President, Corporate Development of Conforma Therapeutics from April 2004 to May 2006 where he negotiated its acquisition by Biogen IDEC for $250 million. From July 1998 to April 2004 Mr. LeMasters worked in the Corporate Business Development group at Eli Lilly & Company and was responsible for the successful negotiation of numerous partnerships and licenses across a range of therapeutic areas. Earlier in his career, he was a management consultant with Coopers & Lybrand Consulting and an operational auditor with Owens Corning. Mr. LeMasters currently serves as a board member of Aarden Pharmaceuticals, where he is also a co-founder, and as a board member of the Hoosier Cancer Research Network, a clinical research organization and as a board member of Promosome.
- Jamie A. Donadio
Jamie A. Donadio，自2013年3月以来担任本公司的财务副总裁。在加入本公司之前，他曾于2001年4月-2013年1月期间，在Amylin Pharmaceuticals工作。2011年11月-2013年1月期间，他曾在Amylin担任高级财务总监。2010年12月-2011年11月期间，曾在Amylin担任企业财务规划和分析总监；2007年3月-2007年12月期间，曾担任SEC报告总监；2001年4月-2007年3月期间，曾在Amylin担任各种企业会计职位。2000年12月-2001年4月期间，他曾是Novatel Wireless股份有限公司的高级会计师。1997年8月-2000年12月期间，曾在Ernst & Young LLP工作，最后担任高级审计。他拥有巴森学院（Babson College）的会计学学士学位，以及是加州（California）的一位非执业注册会计师。
Jamie A. Donadio has served as our Senior Vice President and Chief Financial Officer since March 2016 and Vice President, Finance from March 2013 through March 2016. Prior to joining us, Mr. Donadio was at Amylin Pharmaceuticals from April 2001 through January 2013. From November 2011 to January 2013 Mr. Donadio served as Senior Director of Finance at Amylin. From December 2010 to November 2011 he served as Director of Corporate Financial Planning and Analysis at Amylin. From March 2007 to December 2010 he served as Director of SEC Reporting and from April 2001 to March 2007 he held various corporate accounting roles at Amylin. From December 2000 to April 2001 Mr. Donadio was senior accountant at Novatel Wireless, Inc. From August 1997 to December 2000 Mr. Donadio was with Ernst & Young LLP, last serving as an audit senior. Mr. Donadio holds a B.S. in Accounting from Babson College and is a certified public accountant inactive in the State of California.- Jamie A. Donadio，自2013年3月以来担任本公司的财务副总裁。在加入本公司之前，他曾于2001年4月-2013年1月期间，在Amylin Pharmaceuticals工作。2011年11月-2013年1月期间，他曾在Amylin担任高级财务总监。2010年12月-2011年11月期间，曾在Amylin担任企业财务规划和分析总监；2007年3月-2007年12月期间，曾担任SEC报告总监；2001年4月-2007年3月期间，曾在Amylin担任各种企业会计职位。2000年12月-2001年4月期间，他曾是Novatel Wireless股份有限公司的高级会计师。1997年8月-2000年12月期间，曾在Ernst & Young LLP工作，最后担任高级审计。他拥有巴森学院（Babson College）的会计学学士学位，以及是加州（California）的一位非执业注册会计师。
- Jamie A. Donadio has served as our Senior Vice President and Chief Financial Officer since March 2016 and Vice President, Finance from March 2013 through March 2016. Prior to joining us, Mr. Donadio was at Amylin Pharmaceuticals from April 2001 through January 2013. From November 2011 to January 2013 Mr. Donadio served as Senior Director of Finance at Amylin. From December 2010 to November 2011 he served as Director of Corporate Financial Planning and Analysis at Amylin. From March 2007 to December 2010 he served as Director of SEC Reporting and from April 2001 to March 2007 he held various corporate accounting roles at Amylin. From December 2000 to April 2001 Mr. Donadio was senior accountant at Novatel Wireless, Inc. From August 1997 to December 2000 Mr. Donadio was with Ernst & Young LLP, last serving as an audit senior. Mr. Donadio holds a B.S. in Accounting from Babson College and is a certified public accountant inactive in the State of California.
- Charles M. Baum
Charles M. Baum, M.D., Ph.D.，自2012年11月以来，担任本公司的总裁、首席执行官，以及是一位董事会成员。2003年6月-2012年9月期间，他曾在辉瑞（Pfizer）担任高级副总裁，负责辉瑞（Pfizer）全球研发部门的生物治疗法临床研究；以及担任副总裁、肿瘤学发展主管和首席医疗官，负责辉瑞（Pfizer）的生物疗法和生物创新中心。2000-2003年期间，他曾在被Merck 收购的公司-Schering-Plough负责数个抗肿瘤化合物的发展。他的职业生涯包括在Stanford大学和Emory大学的学术和医院职位，以及在医药行业担任的数个职责范围不断加大的职位，这些公司包括：SyStemix, Inc. （acquired by Novartis AG）， G.D. Searle & Company （acquired by Pfizer）， Schering-Plough Corporation （acquired by Merck） and Pfizer. Baum博士是在Missouri 州圣路易斯（St. Louis）的Washington大学医学院获得他的医学学士学位和医学博士学位（免疫学专业）的；以及是在斯坦福大学（Stanford University）完成他的博士后教育的。
Charles M. Baum has agreed to serve on our board of directors following the completion of this offering. Dr. Baum has been the President and Chief Executive Officer and a member of the board of directors of Mirati Therapeutics, Inc. since November 2012. From June 2003 to September 2012 he was at Pfizer as Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division and as Vice President and Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. From 2000 to 2003 he was responsible for the development of several oncology compounds at Schering-Plough Corporation acquired by Merck. His career has included academic and hospital positions at Stanford University and Emory University, as well as positions of increasing responsibility within the pharmaceutical industry at SyStemix, Inc. (acquired by Novartis AG), G.D. Searle & Company (acquired by Pfizer), Schering-Plough Corporation (acquired by Merck) and Pfizer. Dr. Baum has served on the board of directors of Immunomedics, Inc. (Nasdaq:IMMU) since February 2019 and was on the board of directors of Array BioPharma Inc. from 2014 until its acquisition by Pfizer in July 2019. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-doctoral training at Stanford University.- Charles M. Baum, M.D., Ph.D.，自2012年11月以来，担任本公司的总裁、首席执行官，以及是一位董事会成员。2003年6月-2012年9月期间，他曾在辉瑞（Pfizer）担任高级副总裁，负责辉瑞（Pfizer）全球研发部门的生物治疗法临床研究；以及担任副总裁、肿瘤学发展主管和首席医疗官，负责辉瑞（Pfizer）的生物疗法和生物创新中心。2000-2003年期间，他曾在被Merck 收购的公司-Schering-Plough负责数个抗肿瘤化合物的发展。他的职业生涯包括在Stanford大学和Emory大学的学术和医院职位，以及在医药行业担任的数个职责范围不断加大的职位，这些公司包括：SyStemix, Inc. （acquired by Novartis AG）， G.D. Searle & Company （acquired by Pfizer）， Schering-Plough Corporation （acquired by Merck） and Pfizer. Baum博士是在Missouri 州圣路易斯（St. Louis）的Washington大学医学院获得他的医学学士学位和医学博士学位（免疫学专业）的；以及是在斯坦福大学（Stanford University）完成他的博士后教育的。
- Charles M. Baum has agreed to serve on our board of directors following the completion of this offering. Dr. Baum has been the President and Chief Executive Officer and a member of the board of directors of Mirati Therapeutics, Inc. since November 2012. From June 2003 to September 2012 he was at Pfizer as Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division and as Vice President and Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. From 2000 to 2003 he was responsible for the development of several oncology compounds at Schering-Plough Corporation acquired by Merck. His career has included academic and hospital positions at Stanford University and Emory University, as well as positions of increasing responsibility within the pharmaceutical industry at SyStemix, Inc. (acquired by Novartis AG), G.D. Searle & Company (acquired by Pfizer), Schering-Plough Corporation (acquired by Merck) and Pfizer. Dr. Baum has served on the board of directors of Immunomedics, Inc. (Nasdaq:IMMU) since February 2019 and was on the board of directors of Array BioPharma Inc. from 2014 until its acquisition by Pfizer in July 2019. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-doctoral training at Stanford University.
- Isan Chen
Isan Chen, M.D.，自2013年9月以来，是本公司的副执行总裁以及医疗和发展总监。他是经董事会认证的在内科、血液病学和肿瘤内科学领域拥有超过15年的肿瘤以及从人类到全球注册研究临床试验的经验。他拥有肿瘤临床发展和与美国（United States）和欧洲（Europe）监管机构合作的经验。他最近是在一家2013年7月被Johnson & Johnson收购的公司- Aragon Pharmaceuticals担任首席医疗官。在Aragon Pharmaceuticals，Chen博士曾负责该公司的所有项目临床发展战略，包括前列腺癌和乳腺癌。在加入Aragon Pharmaceuticals之前，他曾在辉瑞（Pfizer）的肿瘤业务部担任肿瘤策略副总裁。另外，他还曾是一种2006年经FDA通过的指示法、治疗肾细胞癌多激酶抑制剂- Sutent的临床负责人。他还曾是克里唑蒂尼（crizotinib）和CDK4/6抑制剂palbociclib1期临床试验负责人。他是在San Diego 市California大学完成他的血液病学/肿瘤学研究员职位的。在加入辉瑞（Pfizer）之前，他曾在加州洛杉矶希望城医学中心（City of Hope Medical Center）作为一位主治医师从事医学的，随后担任Texas大学的副教授、安德森癌症中心（Anderson Cancer Center）医学博士。
Isan Chen, M.D. has served as our Executive Vice President and Chief Medical and Development Officer since September 2013. Dr. Chen is board certified in Internal medicine, hematology and medical oncology with more than 15 years of experience in oncology and clinical trials from first-in-humans through global registrational studies. He has experience in oncology clinical development and interactions with regulatory agencies in the United States and Europe. He was most recently the Chief Medical Officer of Aragon Pharmaceuticals, which was acquired by Johnson & Johnson in July of 2013. At Aragon Pharmaceuticals, Dr. Chen was responsible for the clinical development strategy of all the company's programs, including prostate and breast cancer. Prior to Aragon Pharmaceuticals, Dr. Chen served as Vice President of tumor strategy in the oncology business unit at Pfizer. In addition he was the clinical lead for Sutent, a multiple kinase inhibitor, for the treatment of RCC, an indication in which the drug secured FDA approval in 2006. He was also the clinical lead for the Phase 1 studies of crizotinib and CDK 4/6 inhibitor palbociclib. Dr. Chen completed his hematology/oncology fellowship at University of California, San Diego. Before joining Pfizer, Dr. Chen practiced medicine as a staff physician at City of Hope Medical Center and later as an assistant professor at the University of Texas, M.D. Anderson Cancer Center.- Isan Chen, M.D.，自2013年9月以来，是本公司的副执行总裁以及医疗和发展总监。他是经董事会认证的在内科、血液病学和肿瘤内科学领域拥有超过15年的肿瘤以及从人类到全球注册研究临床试验的经验。他拥有肿瘤临床发展和与美国（United States）和欧洲（Europe）监管机构合作的经验。他最近是在一家2013年7月被Johnson & Johnson收购的公司- Aragon Pharmaceuticals担任首席医疗官。在Aragon Pharmaceuticals，Chen博士曾负责该公司的所有项目临床发展战略，包括前列腺癌和乳腺癌。在加入Aragon Pharmaceuticals之前，他曾在辉瑞（Pfizer）的肿瘤业务部担任肿瘤策略副总裁。另外，他还曾是一种2006年经FDA通过的指示法、治疗肾细胞癌多激酶抑制剂- Sutent的临床负责人。他还曾是克里唑蒂尼（crizotinib）和CDK4/6抑制剂palbociclib1期临床试验负责人。他是在San Diego 市California大学完成他的血液病学/肿瘤学研究员职位的。在加入辉瑞（Pfizer）之前，他曾在加州洛杉矶希望城医学中心（City of Hope Medical Center）作为一位主治医师从事医学的，随后担任Texas大学的副教授、安德森癌症中心（Anderson Cancer Center）医学博士。
- Isan Chen, M.D. has served as our Executive Vice President and Chief Medical and Development Officer since September 2013. Dr. Chen is board certified in Internal medicine, hematology and medical oncology with more than 15 years of experience in oncology and clinical trials from first-in-humans through global registrational studies. He has experience in oncology clinical development and interactions with regulatory agencies in the United States and Europe. He was most recently the Chief Medical Officer of Aragon Pharmaceuticals, which was acquired by Johnson & Johnson in July of 2013. At Aragon Pharmaceuticals, Dr. Chen was responsible for the clinical development strategy of all the company's programs, including prostate and breast cancer. Prior to Aragon Pharmaceuticals, Dr. Chen served as Vice President of tumor strategy in the oncology business unit at Pfizer. In addition he was the clinical lead for Sutent, a multiple kinase inhibitor, for the treatment of RCC, an indication in which the drug secured FDA approval in 2006. He was also the clinical lead for the Phase 1 studies of crizotinib and CDK 4/6 inhibitor palbociclib. Dr. Chen completed his hematology/oncology fellowship at University of California, San Diego. Before joining Pfizer, Dr. Chen practiced medicine as a staff physician at City of Hope Medical Center and later as an assistant professor at the University of Texas, M.D. Anderson Cancer Center.
- James Christensen
James Christensen, Ph.D.，自2014年1月以来是本公司的高级副总裁和首席科技官。2013年6月-2014年1月期间，担任本公司的研究副总裁。在加入本公司之前，他曾于2007一直到2011年4月期间，在Pfizer的肿瘤研究部担任转译研究总监；2011年4月-2013年6月期间担任肿瘤研究部精准药物高级总监。2003年加入辉瑞（Pfizer）的他，负责领导肿瘤项目的非临床研究事务，包括苹果酸舒尼替尼（sunitinib malate）研究活动，以及领导其他研究和发展项目（包括克里唑蒂尼（crizotinib））的非临床和转译生物技术工作。他曾于2005-2013年期间，作为癌症研究或者肿瘤研究部的一位领导成员参与事务。在2003年之前，他曾是一家被Pharmacia Corporation收购、现为辉瑞（Pfizer）拥有的公司- SUGEN股份有限公司的临床前研究和探索研究的团体负责人。Christensen博士是于1998年在Warner Lambert（现为辉瑞（Pfizer）拥有）开始他的职业生涯的，专注于肿瘤疗法领域的RTK生物学和RTK生物标志物的发展研究。他目前在癌症研究和分子癌症疗法编辑部工作。他是在North Carolina州立大学以癌变过程中凋亡失调机制描述方向的论文研究获得他的分子药物学博士学位的。
James Christensen, Ph.D. has served as our Senior Vice President, and Chief Scientific Officer since January 2014 and served as our Vice President, Research from June 2013 through January 2014. Prior to joining us, he held various positions at Pfizer from 2003 to 2013 the most recent of which was Senior Director of Oncology Precision Medicine in the Oncology Research Unit. Dr. Christensen joined Pfizer in 2003 and his responsibilities there included leading nonclinical research efforts for oncology programs including sunitinib malate research activities and leading the nonclinical and translational biology efforts for other research and development programs including crizotinib. Dr. Christensen participated as a member of the Cancer Research or Oncology Research Unit leadership team from 2005 to 2013. Prior to 2003 Dr. Christensen was a Group Leader on the Preclinical Research and Exploratory Development team at SUGEN, Inc., which was acquired by Pharmacia Corporation, now owned by Pfizer. Dr. Christensen began his career in 1998 at Warner Lambert, now owned by Pfizer, with research focus in RTK biology and RTK pathway biomarker development in the oncology therapeutic area. Dr. Christensen participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics. Dr. Christensen received a Ph.D. in molecular pharmacology from North Carolina State University with dissertation research directed toward characterization of mechanisms of apoptosis dysregulation during the process of carcinogenesis.- James Christensen, Ph.D.，自2014年1月以来是本公司的高级副总裁和首席科技官。2013年6月-2014年1月期间，担任本公司的研究副总裁。在加入本公司之前，他曾于2007一直到2011年4月期间，在Pfizer的肿瘤研究部担任转译研究总监；2011年4月-2013年6月期间担任肿瘤研究部精准药物高级总监。2003年加入辉瑞（Pfizer）的他，负责领导肿瘤项目的非临床研究事务，包括苹果酸舒尼替尼（sunitinib malate）研究活动，以及领导其他研究和发展项目（包括克里唑蒂尼（crizotinib））的非临床和转译生物技术工作。他曾于2005-2013年期间，作为癌症研究或者肿瘤研究部的一位领导成员参与事务。在2003年之前，他曾是一家被Pharmacia Corporation收购、现为辉瑞（Pfizer）拥有的公司- SUGEN股份有限公司的临床前研究和探索研究的团体负责人。Christensen博士是于1998年在Warner Lambert（现为辉瑞（Pfizer）拥有）开始他的职业生涯的，专注于肿瘤疗法领域的RTK生物学和RTK生物标志物的发展研究。他目前在癌症研究和分子癌症疗法编辑部工作。他是在North Carolina州立大学以癌变过程中凋亡失调机制描述方向的论文研究获得他的分子药物学博士学位的。
- James Christensen, Ph.D. has served as our Senior Vice President, and Chief Scientific Officer since January 2014 and served as our Vice President, Research from June 2013 through January 2014. Prior to joining us, he held various positions at Pfizer from 2003 to 2013 the most recent of which was Senior Director of Oncology Precision Medicine in the Oncology Research Unit. Dr. Christensen joined Pfizer in 2003 and his responsibilities there included leading nonclinical research efforts for oncology programs including sunitinib malate research activities and leading the nonclinical and translational biology efforts for other research and development programs including crizotinib. Dr. Christensen participated as a member of the Cancer Research or Oncology Research Unit leadership team from 2005 to 2013. Prior to 2003 Dr. Christensen was a Group Leader on the Preclinical Research and Exploratory Development team at SUGEN, Inc., which was acquired by Pharmacia Corporation, now owned by Pfizer. Dr. Christensen began his career in 1998 at Warner Lambert, now owned by Pfizer, with research focus in RTK biology and RTK pathway biomarker development in the oncology therapeutic area. Dr. Christensen participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics. Dr. Christensen received a Ph.D. in molecular pharmacology from North Carolina State University with dissertation research directed toward characterization of mechanisms of apoptosis dysregulation during the process of carcinogenesis.